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In the past 25 years, the development of an eﬀective malaria vaccine has become one of the biggest riddles in the biomedical
sciences. Experimental data using animal infection models demonstrated that it is possible to induce protective immunity against
diﬀerent stages of malaria parasites. Nonetheless, the vast body of knowledge has generated disappointments when submitted
to clinical conditions and presently a single antigen formulation has progressed to the point where it may be translated into a
human vaccine. In parallel, new means to increase the protective eﬀects of antigens in general have been pursued and depicted,
such as the use of bacterial ﬂagellins as carriers/adjuvants. Flagellins activate pathways in the innate immune system of both mice
and humans. The recent report of the ﬁrst Phase I clinical trial of a vaccine containing a Salmonella ﬂagellin as carrier/adjuvant
may fuel the use of these proteins in vaccine formulations. Herein, we review the studies on the use of recombinant ﬂagellins as
vaccine adjuvants with malarial antigens in the light of the current state of the art of malaria vaccine development. The available
informationindicates that bacterial ﬂagellins should be seriously considered for malaria vaccine formulationsto the development
of eﬀective human vaccines.
1.Whole Parasite Vaccines
1.1. Preerythrocytic Stages. The seminal work using radia-
tion-attenuated sporozoites has been reproduced in mul-
tiple experimental systems, demonstrating that attenuated
infective forms of Plasmodium sp. administered by the
endovenous route can provide solid vaccination status
against any symptoms of malaria [1]. However, the use
of radiation-attenuated, viable live sporozoites imposes a
number of restrictions because if the radiation fails, then
these parasites would cause the disease, thereby nullifying
any protective eﬀects. To deﬁnitively solve this problem, a
number of genetically attenuated lines of parasites have been
recently generated. These genetically attenuated parasites are
now being pursued as possible antigenic sources for vaccine
development for humans, and Phase I and II studies are
about to begin [2–5].
1.2. Erythrocytic Stages. Likewise, genetically attenuated
blood-stage forms of rodent malaria parasites have been
successfully generated in the past few years and have been2 Journal of Parasitology Research
proposed as an antigen source for human vaccination trials
[5–7]. To our knowledge, none of these parasite lines are
being tested in Phase I or II trials. Although it is technically
feasible to produce large amounts of genetically attenuated
sporozoites or blood-stage forms, it would be diﬃcult to
commercialise these vaccines because the parasites would
have to be injected live (cryopreserved) by the endovenous
route to confer protective immunity. There are also safety
issues related to intravenous injections of these formulations
because vaccines are not conventionally administered by
this route. These two issues will certainly become the main
obstaclesthatmustbeovercomeforsuccessful wholeparasite
vaccine development.
2.RecombinantSubunitVaccines
The diﬃculties associated with large-scale generation of
whole parasite antigens for mass vaccination led to the
search for recombinant subunit vaccines based on immun-
odominant malarial antigens. Again, the mouse malaria
model was very instructive for narrowing the search for the
most promising antigens and testing diﬀerent recombinant
formulations, which provided the proof of principle for
these subunit recombinant vaccines. Based on many years
of detailed studies, some leading candidate antigens and
formulations for vaccines were selected and exhaustively
tested, but these tests have mainly occurred in the mouse
model of infection as well as nonhuman primates.
2.1. Preerythrocytic Stages. Immunity generated by
radiation-attenuated sporozoites is targeted to a dominant
protective antigen, the circumsporozoite (CS) protein
[8]. Nevertheless, other protective antigens yet to be
characterized do exist [8, 9]. This protein is recognized
by antibodies, CD4+ and CD8+ T cells induced by immu-
nisation with radiation-attenuated sporozoites that can
eliminate the pre-erythrocytic stages of the parasite [10–14].
These results led to the developmentof vaccine formulations
that elicit high antibody titres against sporozoites and/or
increased numbers of CD4+ and CD8+ T cells speciﬁc
f o rm a l a r i al i v e rs t a g e s .A l t h o u g ho t h e rp r o t e i n ss u c ha s
Liver Stage 1 or 3 and Thrombospondin-Related Anony-
mous Protein (TRAP) are also being explored as vaccine
candidates, the CS protein can be used as a prototypical
example of a pre-erythrocytic stage antigen, and the results
can be extrapolated to the other surface antigens.
High antibody titres can be achieved, for example,
using multiple synthetic peptides (MAPs) formulated in
the presence of strong adjuvants [15–17]. Because of the
successin rodent models, human safety and eﬃcacytrials are
warranted.
The most reliable and reproducible results of vaccination
against pre-erythrocytic stages in rodent malaria models
were obtained by vaccination with two recombinant viral
vectors. Using attenuated viruses containing the entire CS
protein or its immunodominant epitopes, a solid and long-
lasting protective immunity against sporozoite challenge was
elicited [18–20]. Although some protocols managed to use
onlyasinglevectorforvaccination[21],heterologousprime-
boostvaccinationusingtwodiﬀerentvectorsforprimingand
boosting may be essential for eliciting protective immunity
[22–25].
These exciting results obtained in the mouse model led
to a number of clinical trials. Unfortunately, these trials
provided only limited protective immunity in Phase II trials
performed in the laboratory, and none in the ﬁeld [26–28].
The reasons for such failures are diﬃcult to explain precisely.
The failures may be related to low antibody levels and/or
fewer speciﬁc CD4+ and CD8+ T cells generated by these
recombinant viruses in humans compared to mice. Based
on the mouse model, relatively large amounts of CD4+ and
CD8+ T cells are required for complete protective immunity
because high numbers of these cells are already required to
patrol theentire liver[13,18,19,29,30].Morepowerful viral
vectors and strategies of vaccination are being developed
every day, and future approaches may increase the number
of these protective T cells. Nevertheless, it is unclear whether
it will ever be possible to reproduce in humans the levels
of immunity induced by viral vectors that are found in the
mouse models.
Despite the great progress in malaria vaccine research
against pre-erythrocytic stages in the past 20 years, a single
typeofformulationhas shown promising results when tested
in humans. This vaccine formulation consists of a large
C-terminal fragment of the CS protein sequence fused to
the Hepatitis B antigen S (conventional hepatitis B vaccine,
Engerix B) and expressed as a recombinant protein in
Saccharomyces cerevisiae. The fusion protein, named RTS,
when expressed together with antigen S, naturally assembles
into virus-like particles called RTS,S. The eﬃcacy of the
RTS,S formulation is dependent on the use of adjuvant
systems (AS), which consist of two diﬀerent formulations
that include monophosphoryl lipid A (MPL, a detoxiﬁed
form of LPS) and QS21 (saponin puriﬁed from Quillaja
saponaria) in an oil-in-water emulsion (AS02) or in a
liposomal suspension (AS01) [31].
In recent Phase II trials performed in na¨ ıve human vol-
unteers challenged with P. falciparum sporozoites, eﬃcacies
ranging from 32% to 50% were observed. Immunological
studies performed on these vaccinated individuals indicated
that protection correlated with the concentration of speciﬁc
antibodies and the frequency of IFN-γ producing cells as
detected by ELISPOT [32]. A number of Phase IIb trials
have been carried out, and they continue to be carried out
in the ﬁeld. These results are more diﬃcult to interpret, but
in trials performed in children in the endemic areas, 49.5%
and 62% eﬃcacy were reported during the 6-month period
that was studied retarding the ﬁrst malaria episode [33, 34].
Although partial, the protective immunity aﬀorded by this
vaccination protocol can be considered the most hopeful
path for vaccine development to date. Because protective
immunity was highly dependent on the adjuvants used in
the formulation, these studies highlighted the importance
of adjuvant development for a reliable malaria vaccine (see
below). Currently, this formulation is being tested in Phase
III trials in malaria-endemic areas, and the results are
anxiously expected for the years 2011-12 [31].Journal of Parasitology Research 3
2.2. Erythrocytic Stages. The erythrocytic forms of malaria
grow and multiplywithin the host erythrocytes, and therup-
ture of the host cells is responsible for the clinical symptoms,
including fever, of the noncomplicated forms of the disease.
Nevertheless, infected erythrocytes (iEs) can also cytoadhere
by means of variant surface antigens (VSA) to endothelial
receptors on the microvasculature of certain organs or to the
placental trophoblast, thereby disappearing from peripheral
blood circulation. This phenomenon, named sequestration,
isresponsibleforthemajorityofthedeathscausedbymalaria
because it leads to the severe forms of malaria, including
cerebral malaria, severe anaemia, acute respiratory distress
symptoms or pregnancy-associated malaria (PAM) [35].
Because blood-stage forms of the parasite are responsible for
the clinical manifestations of the disease, a vaccine against
them would prevent or reduce the morbidity and mortality
of malaria through the elimination or reduction of the
parasitic burden (reviewed in [36, 37]).
In the case of PAM, the scenario is complex because
cytoadherence is mediated by VSA. Given that P. falciparum
erythrocyte membrane protein-1 (PfEMP-1) is involved
on parasite cytoadhesion and several studies indicate that
PfEMP-1 is the major target during natural acquired immu-
nity, this protein family is the only VSA under consid-
eration for vaccine development based on the induction
of adhesion-blocking antibodies (reviewed in [38]). Fur-
thermore, because PAM is associated with a selection of
antigenically distinct iEs that express a particular PfEMP-
1 variant named VAR2CSA, a speciﬁc vaccine against this
syndrome, based on this variant, should also be developed
[35]. Several bodies of evidence point the VAR2CSA protein
as a leading vaccine candidate against PAM and strategies
based on induction of antibodies capable of inhibiting
the adhesion of iEs to chondroitin sulphate A (CSA) in
the placenta have recently been pursued [38, 39]. In fact,
disruption of var2csa gene abrogates iEs CSA binding ability,
plasma antibody levelsagainst VAR2CSAare gender-speciﬁc,
and naturally acquisition of high levels of VAR2CSA speciﬁc
antibodies is parity-dependent and correlates to protection
against PAM. However, large-scale development of a full-
lengthVAR2CSArecombinantproteinishampered byitssize
(350kDa). An alternative is the expression of all or some
of its six Duﬀy binding-like (DBL) domains, although full-
length VAR2CSA displays higher speciﬁcity and aﬃnity to
humanCSAandinducedantibodiesabrogateadhesion ofiEs
to CSA [40]. Nevertheless, detailed characterization regard-
ingVAR2CSADBLdomains interactionwith CSAbackbone,
the resolution of their molecular structure (individually or
as large fragments), and their involvement in PAM are still
puzzling [38, 39].
Concerning blood-stage antigens of Plasmodium not
directly related to PAM, in the last 20 years signiﬁcant
progress has been made in their molecular characterisation
as well as in the identiﬁcation of the immunologic mech-
anisms capable of eliminating these forms of the parasite
(reviewed in [41–43]). Among the immunodominant anti-
gens already characterised from blood-stage parasites, one
of the main candidates for the development of a vaccine
against PlasmodiumistheMerozoiteSurfaceProtein1(MSP-
1) (revised in [44]). Although other proteins, such as Apical
Membrane Antigen 1 (AMA-1) and Duﬀy-Binding Protein
(DBP),are also being explored as vaccine candidates (revised
in [45–47]), MSP-1 can be used as a prototypical example
of a blood-stage antigen, and the results obtained from a
vaccine developed around this antigen can be extrapolated
to other surface antigens.
IndiﬀerentspeciesofPlasmodium,thestructureoftheC-
terminal region ofMSP-1 (MSP119) consists of twodomains.
These domains contain 10–12 cysteine residues. Domain 1
o r2c o n t a i n4 – 6o r6c y s t e i n er e s i d u e sa n df o r m2 - 3o r3
disulphide bonds, respectively. Both domains are conﬁgured
as epidermal growth factor-(EGF-) like domains. This type
of conformation was initially suggested by the primary
amino acid structure and was later conﬁrmed by the three-
dimensional analysis of recombinant proteins representing
the MSP119 regions of P. cynomolgi and P. falciparum.T h e
structure of the MSP119 of P. vivax (PvMSP119)w a sr e c e n t l y
elucidated through NMR, and it corroborated the MSP119
structures previously described in other species [48].
During invasion of the host erythrocytes, MSP-1 is a
target of proteolytic processes. Various studies have demon-
strated that MSP142 is found as a dimer, while MSP119
remains monomeric, suggesting a secondary process that
would cause the dissociation of the protein before the
erythrocytes are invaded (reviewed in [44]).
The precise biological role of MSP-1 is still unknown.
However, several studies have demonstrated that antibodies
speciﬁc for the MSP119 of P. falciparum (PfMSP119)c a n
inhibit the invasion of merozoites, suggesting that this
protein is involved in the process of erythrocyte invasion.
In this context, attempts to knock down the coding genes
of six merozoite proteins of P. falciparum associated with
the membrane through the GPI anchor (MSP-1, MSP-2,
MSP-4, MSP-5, MSP-10, RAMA, and Pf92) demonstrated
that successful genetic deletion could not be obtained,
with the exception of the msp-5 gene. These observations
highlight the importance of these proteins in the blood
cycle of the malaria parasite [49, 50]. Finally, developmental
knockout proved the importance of MSP-1 in the structure
of Plasmodium merozoites [51].
Based on these positive attributes, the C-terminal region
of MSP-1 (MSP119 or MSP142) has been heavily pursued as
a vaccine candidate. Initial studies in mouse models demon-
strated solid levels of protective immunity after vaccination
with strong adjuvants, such as Complete Freund’s Adjuvant
[52, 53]. Other adjuvants did not elicit a similar eﬀect,
which clearly demonstrates the importance of the adjuvant
in vaccine formulations. Although protective immunity is
mostly mediated by antibodies, a recent study showed that
t h ep r e s e n c eo fC D 4 + T helper epitopesimproves the protec-
tive immunity induced in mouse models [54]. Subsequent
studies performed in nonhuman primates duplicated these
results by demonstrating a strict requirement for a strong
adjuvant (e.g., Complete Freund’s Adjuvant) to stimulate
protective immunity against experimental infection with P.
cynomolgi or P. falciparum [55, 56].4 Journal of Parasitology Research
Based on the results obtained from the experimental
models of malaria infection, a recent Phase IIb vaccine trial
was performed in Africa. In this clinical trial, children were
vaccinated with a formulation containing a recombinant
His-tagged fusion protein encompassing the MSP142 of
the P. falciparum 3D7 strain (FMP1) that was formulated
with the adjuvant AS02 [57]. This vaccine formulation was
shown to be safe and immunogenic, as demonstrated by
detectionofspeciﬁc antibody titres by ELISA.Unfortunately,
the trial failed, and no signiﬁcant reduction in the inci-
dence of malaria infection could be observed in children
receiving the FMP1/AS02 formulation [57]. The precise
reason why the vaccination failed should be investigated.
It might be attributed to a polymorphism of the MSP-1
protein. This fact may be relevant to the interpretation of
t h er e s u l t sb e c a u s ep r o t e c t i v ei m m u n i t yt ot h eC - t e r m i n a l
region of P. falciparum MSP-1 can be strain-speciﬁc, and
antibodies targeting this antigen may not show parasite
inhibitory activity [56]. Furthermore, some of the MSP-1-
speciﬁc antibodies are endowed with the ability to block
the activity of inhibitory antibodies [44]. Although negative,
these results do not completely refute the hypothesis that
the C-terminal region of P. falciparum MSP-1 could be
part of a subunit malaria vaccine in a new recombinant
formorformulation.Currently,theimmunogenicproperties
of distinct recombinant proteins are being compared in
experimental animal models to select possible candidates for
human trials [58].
3.BacterialFlagellinFusionProteins:
BridgingtheGapbetweenMiceandHumans?
As thoroughly discussed above, vaccination of mice with
recombinant proteins or viral vectors may confer signiﬁcant
protection against an infectious challenge with malaria par-
asites. The main problem is that some of these formulations,
such as the ones containing strong adjuvants, simply cannot
be used in humans. Others, such as the recombinant viruses,
failed to reproduce in humans the immunogenicity observed
in mice. These successive failures have led to the search for
newalternativesthatcouldeventuallybridgethegapbetween
mice and humans.
3.1. Bacterial Flagellins. Flagella represent a complex loco-
motion device expressed by diﬀerent bacterial species. They
encompass at least 50 diﬀerent proteins. Flagella may also
behave as virulence-associated factors by helping pathogenic
bacteria to bind to epithelial cells and to overcome non-
immune defence mechanisms such as liquid ﬂow in the
urinary tract. Flagellin, the structural protein of the ﬂagellar
ﬁlament, is the most abundant protein of the ﬂagellar
apparatus, which can assemble by the polymerisation of
thousands of ﬂagellin monomers. The molecular masses of
ﬂagellins can vary from 28kDa to 80kDa. The N- and C-
terminal regions of these molecules are highly conserved
among diﬀerent bacterial species and are folded together in
parallel as a packed α-helix structure that is recognised by
innate receptors of the immune system (see below). On the
other hand, the central region shows a striking degree of
sequence heterogeneity, even among ﬂagellins from a single
bacterial species. This heterogeneity has been observed in
Salmonella enterica serovars, an immune escape mechanism
reﬂecting thefactthatmostBcellepitopesareexposedtothis
region of the molecule [59].
Flagellin is a Pathogen-Associated Molecular Pattern
(PAMP) recognised by Pattern Recognition Receptors
(PRRs) in the innate immune system that triggers inﬂamma-
tory responses and activates the adaptative immune system.
At least two classes of PRRs, Toll-like Receptors (TLRs) and
NOD-like Receptors (NLRs), respond to ﬂagellin.
TLR5 is a transmembrane receptor with a conserved
cytoplasmic signalling domain—the Toll/interleukin (IL)-
1 receptor homology domain (TIR), a common signature
for TLRs—that speciﬁcally recognises a conserved site in
the N- and C-terminal regions of ﬂagellin that is formed
after the correct assembly of the molecule; in fact, this site
is essential for the correct ﬂagella assembly [60, 61]. The
receptor is expressed by monocytes, dendritic cells (DCs),
and epithelial cells that sense extracellular ﬂagellin. When
activated, TLR5 signals through the adaptor protein MyD88
to trigger NF-κB activation and the subsequent expression
of proinﬂammatory cytokines. Flagellin also induces the
expression of a number of activation markers in antigen-
presenting cells (APCs), such as CD80, CD86, CD40, and
MHCclassII,all ofwhich augmentantigenpresentation toT
cells [62–67]. Interestingly, ﬂagellin is one of the two proteic
agonist of TLRs.
I nt h ec a s eo ft h eN L R s ,ﬂ a g e l l i nt h a ti se x p r e s s e db y
intracellularly replicating pathogens or speciﬁcally injected
by a secretory apparatus displayed by some bacterial
pathogens, such as S. enterica, activates a multiprotein
cytosolic complex, the inﬂammasome, which is involved in
the regulation of inﬂammation and cell death responses in a
manner dependent on ICE-protease-activating factor (Ipaf)
andneuronalapoptosisinhibitoryprotein5(Naip5)[68,69].
Activation of the inﬂammasome by cytosolic ﬂagellin is
related to the controlof bacterial growth [70,71]andtriggers
Caspase-1 activation followed by proinﬂammatory cell death
(pyroptosis) with secretion ofIL-1β and IL-18and activation
of inducible nitric-oxide synthase, iNOS [68, 72, 73]. A
short C-terminal region of ﬂagellin, which is distinct from
the sequences required for TLR5 activation, is responsible
for Naip5/Ipaf-containing inﬂammasome activation [69].
Nevertheless, it remains elusive whether ﬂagellin binds
directly to Naip5 or Ipaf or if it acts through an undeﬁned
upstream receptor.
Clearly, mammalian cells evolved the ability to very
eﬃciently sense the presence of extra- and intracellular
ﬂagellins and respond with strong inﬂammatory signals
that may ultimately enhance the induction of adaptive
immune defences. Based on these natural properties, bac-
terial ﬂagellins have been intensively investigated as vaccine
adjuvants that can either be co-administered with puriﬁed
recombinant antigens or as a carrier/adjuvant molecule
genetically fused to the target antigen.Journal of Parasitology Research 5
3.2. Bacterial Flagellins As Vaccine Adjuvants. I nt h el a t e8 0 s ,
a seminal work envisaged the use of bacterial ﬂagellins as
carriers/adjuvants for vaccine antigens by cloning synthetic
oligonucleotides encoding speciﬁc B or T-cell epitopes at the
central hypervariable region of the S. Muenchen FliCd ﬂag-
e l l i ne x p r e s s e di na na t t e n u a t e dS. Dublin vaccine strain that
was delivered via mucosal or parenteral routes to mice [74].
Puriﬁed recombinant forms of ﬂagellin genetically fused
to short synthetic oligonucleotides were also successfully
used as subunit vaccines by targeting either inﬂuenza virus
haemagglutinin or an adhesin expressed by enterotoxigenic
Escherichia colistrains evenbeforethe discovery thatﬂagellin
activates innate immune responses [75, 76].
More recently, the description of innate immune recep-
tors that recognise ﬂagellin and their capacity to activate
innateandadaptiveimmuneresponsesintensiﬁedthestudies
testing bacterial ﬂagellins as vaccine adjuvants for the
induction of both antibody and cellular immune responses.
Diﬀerent systems that used ﬂagellins as carriers/adjuvants
for recombinant fusion proteins or with coadministered
recombinant antigens were tested in the last few years;
for a detailed and updated compilation of these data, we
recommend a very recently published paper [77].
For brevity and the purpose of our review, we selected
the vaccine ﬁeld that is highly advanced: the development
of an anti-inﬂuenza vaccine. Two formulations of fusion
proteins of ﬂagellin and inﬂuenza antigen were generated.
First, four tandemcopiesofthe ectodomain ofthe conserved
matrix protein M2 (M2e) of human inﬂuenza A virus
were fused to the C-terminal domain of the ﬂagellin of
Salmonella typhimurium ﬂjB (Type 2). Asecond formulation
was generated by the fusion of the viral haemagglutinin
globular head domain to the C-terminus of ﬂagellin or
in place of the D3 domain (VAX125). All proteins were
expressed as soluble fusion proteins in the E. coli system. The
preclinical studies testing these vaccines reported induction
of strong humoral-speciﬁc immune responses against the
inﬂuenza antigens after immunisation of mice and rabbits
with the recombinant fusion proteins alone. In both cases,
the antibody response was dependent on the physical fusion
of the antigen to the ﬂagellin. Most relevant for vaccination
studies was the fact that immunisation with either construct
protected mice from a lethal challenge with inﬂuenza A virus
and signiﬁcantly reduced weight loss and clinical symptoms
compared to control animals [78, 79].
Based on these successful pre-clinical studies, the
inﬂuenza vaccine candidate VAX125 underwent a com-
plete Phase I clinical trial that tested safety, reactogenicity,
immunogenicity, tolerogenicity, and escalating dose-range.
The results from this trial showed that recombinant ﬂag-
ellin was generally well tolerated by vaccinated individuals.
Importantly, 91% of the individuals who received any dose
of recombinant protein developed titres of neutralising anti-
bodies compatible with protective status against inﬂuenza
infection (http://clinicaltrials.gov/NCT00921947/)[ 80].
3.3. Bacterial Flagellin As a Carrier/Adjuvant for Malaria
Antigens. Based on the great capacity of ﬂagellin to induce
humoral and cellular immune responses against foreign
antigens, we explored the use of this molecule for the
generation of fusion proteins containing malarial antigens.
We selected for our initial studies the 19-kDa C-terminal
region of MSP-1 from P. vivax. This region of MSP-1,
termed PvMSP119, was selected because it is arguably the
most immunogenic region of P. vivax [81]. In immuno-
epidemiological studies performed all around the world,
this molecule has been shown to be highly conserved [82]
and recognised by more than 95% of individuals after their
ﬁrst contact with the P. vivax [83]. Most pertinent for
vaccine development, immunisation of nonhuman primates
with a recombinant protein based on PvMSP119 resulted in
protection against an experimental challenge [84].
PvMSP119 was fused to the C-terminal end of the FliC
ﬂagellin from S. typhimurium. This fusion protein was able
to bind and activate TLR5 that was expressed by in vitro
cultured transfected cells, and it was recognised by serum
from P. vivax malaria patients. Moreover, the fusion protein
was recognised by monoclonal antibodies directed against
the three-dimensional structural epitopes, indicating that it
wascorrectlyfoldedwhenexpressedintheE.colisystem[85].
We immunised mice and rabbits with the recombinant
fusion protein in the absence of any other adjuvant. Immu-
nised animals developed strong, speciﬁc, and long-lasting
antibody-mediated responses. The antibody titres after the
second dose were similar to the ones obtained follow-
ing immunisation with a recombinant protein containing
only the PvMSP119 emulsiﬁed in Complete/Incomplete
Freund’s Adjuvant. Additionally, the antibodies raised after
these immunisations recognised P. vivax merozoites by
immunoﬂuorescence [85].
In the absence of any other adjuvant, the pattern of the
immune response was biased toward a type 2 response, with
a high IgG1/2 ratio and limited amounts of IFN-γ secreted
by the splenic immune cells. Nevertheless, the addition of
other adjuvants to the fusion protein, such as TLR-9 agonist,
modulated the immune response towards a type 1 response,
with a lower IgG1/2 ratio and secretion of signiﬁcantly more
IFN-γ [85].
Because long-term in vitro culture of P. vivax is not
feasible, and itwas diﬃcultto ﬁnd areliable biologicalmodel
to test our vaccine formulation, we reproduced entirely the
study using the 19-kDa C-terminal region of MSP-1 from
P. falciparum. This region of MSP-1, termed PfMSP119,
was selected because it has been extensively studied as a
vaccine candidate, as described above. Rabbits injected with
PfMSP119 fused to ﬂagellin raised high antibody titres that
dramatically inhibited the in vitro growth of the parasite
lines 3D7, S20, and FCR3 [86]. A similar approach is
now being used to generate recombinant fusion proteins
containing immuno-dominant epitopes of the sporozoite
stage CS protein.
Using another approach, we inserted the CS protein
CD8+ T-cell epitope CS280–288) from the murine malaria
parasite P. yoelii into the central hypervariable (D3) domain
of the S. Muenchen FliC ﬂagellin [74]. The ﬂagellin adjuvant
eﬀects were determined with two vaccine formulations: (i)
attenuated S. Dublin strains administered orally expressing6 Journal of Parasitology Research
hybrid ﬂagella composed of the ﬂagellin-CS fusion protein
and (ii) puriﬁed ﬂagellins administered s.c. to mice either
as hybrid ﬂagellin or native ﬂagellin mixed with synthetic
CS280–288 peptide. Both formulations induced CS-speciﬁc
CD8+ T-cell responses in the absence of any conventional
adjuvant, as measured by ELISPOT [87]. These results
suggest that Salmonella ﬂagellins are promising soluble
adjuvants for synthetic peptides in regard to the activation
of speciﬁc cytotoxic T cell responses.
To our knowledge, these were the ﬁrst reports of an
inductionofspeciﬁchumoralandcellularimmuneresponses
in experimental immunisations with recombinant proteins
based on malaria vaccine antigens without the addition of
any conventional adjuvant. As mentioned above, the magni-
tude of an immune response induced against recombinant
proteins is highly dependent on the potency of the adjuvant
formulation.
4.AdjuvanticityMechanism of Flagellin
The mechanisms by which ﬂagellin acts as an adjuvant are
not fully understood, but it is likely to be dependent on
direct APC activation, especially DC activation, to enhance
antigen presentation. Flagellin up-regulates the expression of
costimulatory molecules such as B7-1, B7-2, and CD40 in
murine bone marrow-derived DCs [88, 89]a n dB 7 - 1 ,B 7 -
2, CD83, and CCR7 in human primary blood DCs [62].
Moreover, ﬂagellin-maturated human DCs down-regulate
endocytic activity, a hallmark of DC activation, and they
have enhanced T-cell stimulatory activity [62]. Another
remarkable capacity of ﬂagellin is to convert tolerogenic
DCs into activated antigen-presenting cells, which is an
unusual ability [90]. The eﬀects of ﬂagellin on DCs are at
least in part dependent on TLR5 activation, as evidenced
by the fact that OVA-speciﬁc CD4+ T cell proliferation in
response to immunisation with ﬂagellin-OVA is impaired
by depletion of TLR5+/+CD11c+/+ cells or in TLR5−/−)
mice [67]. However, TLR5−/−) mice still develop strong
antiﬂagellin antibody responses after injection of ﬂagellin; in
addition, MyD88−/−) mice, which have impaired TLR- and
NOD-dependent signalling, respond to ﬂagellin injection
with less robust antibody production [91]. In fact, recent
results have shown that both TLR5 and NOD-like receptors
operate in a complementary manner to support the ﬂagellin
adjuvant eﬀects, at least in relation to the induction of
humoral responses [92].
The requirement for the physical linking of ﬂagellin to
theantigen is still a matter ofdebate.The fusion requirement
may be dependent on the amount of antigen injected. One
possibility is that when ﬂagellin is bound to the antigen,
there is concomitant APC activation and antigen uptake,
as opposed to coadministered soluble antigen and ﬂagellin
when an activated APC may not uptake the antigen at
the same time of activation. The fact that activated DCs
down-regulate endocytic activity supports this hypothesis,
indicating that if activation does not happen in the presence
of the antigen, uptake may be impaired, and more antigen
would be required to increase the chance of concomitant
antigen uptake and APC activation. In fact, when we tested
equimolar amounts of ﬂagellin and antigen that were fused
or co-administered, we found that the responses are compa-
rable in the range of 10μg; however, the fusion protein was
more eﬃcient in the induction of antigen-speciﬁc antibody
responses at the levels of 1μgo r0 . 1 μg( B a r g i e r iD Ya n d
Rodrigues MM, unpublished data).
5.Conclusions
RTS,S is arguably the most advanced vaccine against P.
falciparum malaria. Its development provided great lessons;
for example, we learned that the delivery system/adjuvant is
integral for the induction of any degree of immunity against
malaria. Despite the on-going RTS,S Phase III clinical trials,
we should not stop looking for new methods to improve the
immunogenicity of recombinant antigens in humans. One
possibility would be to add other recombinant vectors, such
as adenoviral vectors, in combination with RTS,S to boost its
potency. In this paper, we proposed an alternative approach
thatinvolvedthestructuralmodiﬁcationofmalarial antigens
toincreasetheirintrinsic immunogenicity.Theuseofrecom-
binantfusionﬂagellins containingmalarial epitopesmaybea
simple and inexpensive way to enhance protein antigenicity.
The fact that recombinant ﬂagellins have reached Phase
I/II clinical trials should accelerate further studies in this
direction.
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